Volume 119, Issue 1, Pages (July 2000)

Slides:

Advertisements

Similar presentations

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Advertisements

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Volume 128, Issue 4, Pages (October 2005)

Blood Pressure Variability at Normal and High Blood Pressure

Volume 121, Issue 4, Pages (October 2001)

AGA technical review on irritable bowel syndrome

Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome–Diarrhea Without Bile Acid Malabsorption Cédric Peleman,

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gerald Holtmann*,

Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia Peter J. Kahrilas*,

Methods for Diagnosis of Bile Acid Malabsorption in Clinical Practice

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects Paolo L. Peghini, Philip O. Katz, Donald.

Management of the irritable bowel syndrome

Volume 144, Issue 5, Pages e3 (May 2013)

Volume 123, Issue 2, Pages (August 2002)

First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori Stephan Timm, Marco Sailer, Karl–hermann.

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera.

Volume 140, Issue 7, Pages (June 2011)

Diagnosis of irritable bowel syndrome

Volume 119, Issue 3, Pages (September 2000)

Lawrence K. Gates, Dawn V. Holladay Gastroenterology

Lisa A. Mueller, Michael Camilleri, Alison M. Emslie–Smith

Simon P. Dunlop, Nicholas S. Coleman, Elaine Blackshaw, Alan C

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? William E. Whitehead, Olafur.

Volume 130, Issue 3, Pages (March 2006)

Volume 118, Issue 1, Pages (January 2000)

Gastric Emptying Clinical Gastroenterology and Hepatology

Volume 132, Issue 1, Pages (January 2007)

Effect of Alvimopan and Codeine on Gastrointestinal Transit: A Randomized Controlled Study Jonathan Gonenne, Michael Camilleri, Irene Ferber, Duane Burton,

A Stable Isotope Breath Test With a Standard Meal for Abnormal Gastric Emptying of Solids in the Clinic and in Research Lawrence A. Szarka, Michael Camilleri,

Volume 139, Issue 5, Pages e1 (November 2010)

13C-octanoic acid breath test for gastric emptying rate of solids

Volume 124, Issue 4, Pages (April 2003)

Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation Michael A. Kamm, Stefan Mueller–Lissner, Arnold Wald, Erika Richter,

Evaluation and Treatment of Obesity

Craig Mowat, Andrew Carswell, Angela Wirz, Kenneth E.L. McColl

Prospective Study of Motor, Sensory, Psychologic, and Autonomic Functions in Patients With Irritable Bowel Syndrome Michael Camilleri, Sanna McKinzie,

Volume 116, Issue 1, Pages (January 1999)

Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial Andres Acosta, Michael Camilleri,

Volume 131, Issue 6, Pages (December 2006)

Volume 116, Issue 3, Pages (March 1999)

The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus Andrea Shin, Michael.

William K. Fackler, Tina M. Ours, Michael F. Vaezi, Joel E. Richter

Severe Constipation Clinical Gastroenterology and Hepatology

Volume 138, Issue 1, Pages (January 2010)

Volume 149, Issue 2, Pages e2 (August 2015)

Volume 151, Issue 1, Pages e6 (July 2016)

Volume 119, Issue 4, Pages (October 2000)

Mark Topazian, Michael Camilleri, Felicity T. Enders, Jonathan E

Volume 141, Issue 5, Pages e7 (November 2011)

Volume 115, Issue 6, Pages (December 1998)

AGA technical review on celiac sprue

Volume 131, Issue 5, Pages (November 2006)

Volume 117, Issue 1, Pages (July 1999)

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome Michael Camilleri, Sanna McKinzie, Jean Fox, Amy Foxx-orenstein,

Volume 121, Issue 5, Pages (November 2001)

Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease Francesco S. Facchini, Nancy.

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gerald Holtmann*,

Volume 114, Issue 5, Pages (May 1998)

Volume 121, Issue 4, Pages (October 2001)

Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans Heather J. Chial, Michael Camilleri, Irene Ferber,

Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function Suwebatu T. Odunsi–Shiyanbade, Michael.

Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine Maria I. Vazquez Roque, Michael Camilleri,

Volume 122, Issue 7, Pages (June 2002)

Volume 122, Issue 4, Pages (April 2002)

Rectal Gas Volume Measured by Computerized Tomography Identifies Evacuation Disorders in Patients With Constipation Seon-Young Park, Disha Khemani, Alfred.

Volume 121, Issue 3, Pages (September 2001)

Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function Suwebatu T. Odunsi–Shiyanbade, Michael.

Volume 128, Issue 4, Pages (April 2005)

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects Paolo L. Peghini, Philip O. Katz, Donald.

Clinical Case: Chronic Constipation

Presentation transcript:

Volume 119, Issue 1, Pages 41-50 (July 2000) Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans Bernard Coulie, Lawrence A. Szarka, Michael Camilleri, Duane D. Burton, Sanna McKinzie, Nancy Stambler, Jesse M. Cedarbaum Gastroenterology Volume 119, Issue 1, Pages 41-50 (July 2000) DOI: 10.1053/gast.2000.8553 Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 1 Experimental protocol of 6-week studies with 2-week lead-in, 2-week treatment, and 2-week washout periods. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 2 Scintigraphic scans showing the effects of r-metHuBDNF and placebo on colonic transit in individual participants. Treatment with r-metHuBDNF resulted in acceleration of colonic transit, with more isotope located in the more distal segment of the colon, and a corresponding increase in GC with r-metHuBDNF treatment. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 3 Individual data for GC at (A) 24 and (B) 48 hours before and after treatment. Data for r-metHuBDNF are shown on the left, and data for placebo on the right. The mean data for each group are indicated by the thick horizontal bar. Most participants who received r-metHuBDNF had higher GC24 values after treatment. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 4 Number of stools per week in the (A) placebo-treated group and (B) r-metHuBDNF–treated group. Placebo or drug was administered in weeks 1 and 2. Individual data points, median and interquartile ranges, and 10th and 90th percentiles (horizontal lines) are shown. The r-metHuBDNF group had an increased stool frequency from the first week of treatment; this effect persisted for a week after cessation of NT administration. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 5 Scintigraphic scans showing the effects of r-metHuNT-3 on colonic transit in a constipated participant. Treatment with r-metHuNT-3 resulted in acceleration of colonic transit, with more isotope located in the more distal segment of the colon, and a corresponding increase in GC with r-metHuNT-3 treatment. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 6 Results of scintigraphic scans showing the effects of r-metHuNT-3 on gastric, small bowel, and colonic transit in constipated participants. Individual data points, median and interquartile ranks, and ranges (horizontal lines) are shown. Treatment with r-metHuNT-3 resulted in acceleration in gastric, small bowel, and colonic transit. SBTT, small bowel transit time; GEt½, gastric half-emptying time. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 7 Individual data for GC at (A) 24 and (B) 48 hours before and after treatment with r-metHuNT-3 in patients with constipation. Mean data for each group are indicated by thick horizontal bars. Dashed lines represent the lower limit of normal based on values obtained in 57 healthy subjects in our laboratory (unpublished data). Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 8 Number of stools per week in (A) constipation and (B) health. r-metHuNT-3 was administered in weeks 1 and 2. The figure shows individual data points, median and interquartile ranges, and ranges (horizontal lines). Both groups showed increased frequency from the first week of treatment; this effect persisted for a week after cessation of NT administration. Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions

Fig. 9 (A) In constipated patients, ease of stool passage was altered during r-metHuNT-3 treatment compared with baseline. (B) Stool consistency tended to be softer during treatment (2, baseline; ■, on treatment). Gastroenterology 2000 119, 41-50DOI: (10.1053/gast.2000.8553) Copyright © 2000 American Gastroenterological Association Terms and Conditions